Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth - 23/11/23
, Mitchell R. Lunn, MD, MAS a, Bertha Chen, MD a, Annesa Flentje, PhD b, Zubin Dastur, MS, MPH a, Micah E. Lubensky, PhD b, Matthew Capriotti, PhD c, Juno Obedin-Maliver, MD, MPH, MAS aAbstract |
Background |
Testosterone use among transgender people likely impacts their experience of sexual function and vulvovaginal pain via several complex pathways. Testosterone use is associated with decreased estrogen in the vagina and atrophic vaginal tissue, which may be associated with decreased vaginal lubrication and/or discomfort during sexual activity. At the same time, increased gender affirmation through testosterone use may be associated with improved sexual function. However, data on pelvic and vulvovaginal pain among transgender men and nonbinary people assigned female at birth are scarce.
Objective |
This study aimed to assess the association between testosterone and sexual function with a focus on symptoms that are commonly associated with vaginal atrophy.
Study Design |
We conducted a cross-sectional analysis of 1219 participants aged 18 to 72 years using data collected from 2019 to 2021 from an online, prospective, longitudinal cohort study of sexual and/or gender minority people in the United States (The Population Research in Identity and Disparities for Equality Study). Our analysis included adult transgender men and gender diverse participants assigned female at birth who were categorized as never, current, and former testosterone users. Sexual function was measured across 8 Patient-Reported Outcomes Measurement Information System Sexual Function and Satisfaction domains.
Results |
Overall, 516 (42.3%) participants had never used testosterone, and 602 (49.4%) currently used testosterone. The median duration of use was 37.7 months (range, 7 days to >27 years). Most participants (64.6%) reported genital pain or discomfort during sexual activity in the past 30 days, most commonly in the vagina or frontal genital opening (52.2%), followed by around the clitoris (29.1%) and labia (24.5%). Current testosterone use was associated with a greater interest in sexual activity (β=6.32; 95% confidence interval, 4.91–7.74), higher ability to orgasm (β=1.50; 95% confidence interval, 0.19-2.81), and more vaginal pain or discomfort during sexual activity (β=1.80; 95% confidence interval, 0.61–3.00). No associations were observed between current testosterone use and satisfaction with sex life, lubrication, labial pain or discomfort, or orgasm pleasure.
Conclusion |
Testosterone use among transgender men and gender diverse people was associated with an increased interest in sexual activity and the ability to orgasm, as well as with vaginal pain or discomfort during sexual activity. Notably, the available evidence demonstrates that >60% of transgender men experience vulvovaginal pain during sexual activity. The causes of pelvic and vulvovaginal pain are poorly understood but are likely multifactorial and include physiological (eg, testosterone-associated vaginal atrophy) and psychological factors (eg, gender affirmation). Given this high burden, there is an urgent need to identify effective and acceptable interventions for this population.
Le texte complet de cet article est disponible en PDF.Key words : dyspareunia, sexual function, testosterone, transgender, vulvovaginal pain
Plan
| J.O.-M. reports receiving consultation fees from Ibis Reproductive Health, Hims Inc., Folx Health Inc., and Sage Therapeutics for topics unrelated to this work. M.R.L. reports receiving consultation fees from Hims Inc., Folx Health Inc., and Otsuka Pharmaceutical Development and Commercialization, Inc. for topics unrelated to this work. All other authors report no conflict of interest. |
|
| This study was funded by the Department of Obstetrics and Gynecology of the Stanford University School of Medicine. Research reported in this article was partially funded by a Patient-Centered Outcomes Research Institute (PCORI) award (award number PPRN-1501-26848) to M.R.L. The statements in this article are solely the responsibility of the authors and do not necessarily represent the views of PCORI or its board of governors or methodology committee or of the National Institutes of Health. A.F. was partially supported by the National Institute on Drug Abuse under grant number K23DA039800. J.O.-M. was partially supported by the National Institute of Diabetes, Digestive, and Kidney Disorders under grant number K12DK111028. The funding sponsors had no role in study design; the data collection, analysis, and interpretation of data; the writing of the report; the decision to submit the article for publication; or in the preparation of the manuscript. |
|
| The findings from this study were presented at the National Transgender Health Summit, San Francisco, CA, May 6–7, 2023. |
|
| We welcome the opportunity to facilitate high-quality, community-engaged research collaborations that aim to improve the health and well-being of LGBTQ+ communities. Through The PRIDE Study’s ancillary studies, a wide variety of investigators working on academic or community-based projects related to LGBTQ+ health can apply to work collaboratively with The PRIDE Study team and access data. For more information, please visit: collaborate |
|
| Cite this article as: Tordoff DM, Lunn MR, Chen B, et al. Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth. Am J Obstet Gynecol 2023;229:669.e1-17. |
Vol 229 - N° 6
P. 669.e1-669.e17 - décembre 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
